Mirador Therapeutics Inc.
- Address
- 4902 Headquarters Point Suite 300
Sponsor Overview
Specializations
Inflammatory Bowel Disease
Mirador Therapeutics Inc. focuses on inflammatory bowel disease research, with clinical interest centered on Crohn’s disease and ulcerative colitis. Its trial activity is directed toward gastrointestinal inflammation, mucosal healing, and the clinical features that define active disease in these conditions.
- Crohn’s disease
- Ulcerative colitis
- Gastrointestinal inflammation
- Mucosal healing
The sponsor’s research landscape includes assessment of disease control in both small bowel and colonic inflammatory presentations.
Endoscopic Disease Assessment
Clinical research activity includes endoscopic response in Crohn’s disease and endoscopic improvement in ulcerative colitis, reflecting a strong emphasis on visual markers of intestinal inflammation and healing. These outcomes are central to understanding treatment effects in gastroenterology and intestinal mucosal disease.
- Endoscopic response
- Endoscopic improvement
- Intestinal mucosal healing
- Gastroenterology
Interest in endoscopic endpoints highlights the sponsor’s focus on objective measures of bowel inflammation.
Clinical Remission and Symptom Control
Mirador Therapeutics Inc. also studies clinical remission in inflammatory bowel disease, with attention to reducing disease activity and improving symptom burden in patients with chronic relapsing intestinal inflammation. This area links immune-mediated disease management with clinically meaningful improvement in patient status.
- Clinical remission
- Symptom control
- Immune-mediated disease
- Chronic relapsing inflammation
The sponsor’s therapeutic interest includes outcomes relevant to both active disease suppression and sustained control of intestinal inflammation.
Safety and Tolerability in Gastrointestinal Therapy
Research activity includes evaluation of safety and tolerability in patients receiving treatment for inflammatory bowel disease, supporting therapeutic development in a population that requires long-term disease management. This area is closely tied to gastrointestinal therapeutics and the practical treatment of chronic inflammatory disorders.
- Safety
- Tolerability
- Gastrointestinal therapeutics
- Chronic inflammatory disorders
The sponsor’s clinical interests extend to treatment-related outcomes that are important in ongoing IBD care.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 2, Multi-Center, Platform Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics with Multiple Therapies in Participants with Active Crohn’s Disease or Active Ulcerative Colitis (ASCEND-IBD) |  Belgium Bulgaria Croatia Czechia Germany Italy Poland Slovakia | Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 39 sites across their trial portfolio.
Therapeutic Focus
- 1.Digestive System Diseases1 trial280 other sponsors
Partnered Research Centres
39 centres- Address
- Via Cherasco 15, 10126 Turin
- Address
- Ul. Mokra 4, 91-034 Lodz
- Address
- Ul. Ul. Ludwika Solskiego 4a/1, 52-416 Wroclaw
- Address
- Hindenburgdamm 30, Lichterfelde, 12203 Berlin
- Address
- Ulitsa Gen. Stefan Toshev 15, 1618 Sofia
- Address
- Ul. Inflancka 4a, 00-189 Warsaw
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Mirador Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.